Home » Regenerative medicine
Category Archives: Regenerative medicine
SEARCH THIS BLOG

Blog Stats
- 4,303,327 hits
Pages
- About me
- All about drugs
- Bioavailability
- CLINICAL TRIALS
- Combinatorial Chemistry in Drug Design
- DISCLAIMER
- Drug Basics
- DRUG COMPANIES
- DRUG DESIGN
- DRUG DISCOVERY
- Drug Information
- DRUG NEWS
- DRUG PORTALS
- Drug resistance
- DRUG SITES
- DRUG SYNTHESIS
- DRUGS NDA
- DRUGS, FDA2012
- FDA -US
- GMP
- HEALTH CANADA
- HELP ME/ ACCOLADES
- HSA SINGAPORE
- INDA
- KOREA DRUG APPROVAL PROCESS
- MHLW JAPAN, 厚生労働省
- NMPA CHINA
- PATENT EXPIRY DATES 1/3
- PATENT EXPIRY DATES 2/3
- PATENT EXPIRY DATES 3/3
- Patent portals
- Polymorphism
- Regulations and Guidance
- Scientificupdate (UK) on a roll
- sFDA CHINA
- SOUTH AFRICA, MCC
- SPECIAL DRUGS
- Traditional Medicine
- WHAT IS A DRUG
- World drug tracker
Archives
- April 2023 (1)
- March 2023 (1)
- January 2023 (5)
- December 2022 (3)
- November 2022 (3)
- October 2022 (9)
- September 2022 (9)
- August 2022 (7)
- July 2022 (2)
- June 2022 (7)
- May 2022 (5)
- April 2022 (7)
- March 2022 (7)
- February 2022 (12)
- January 2022 (15)
- December 2021 (26)
- November 2021 (17)
- October 2021 (21)
- September 2021 (21)
- August 2021 (19)
- July 2021 (13)
- June 2021 (30)
- May 2021 (7)
- April 2021 (9)
- March 2021 (25)
- February 2021 (10)
- January 2021 (17)
- December 2020 (21)
- November 2020 (5)
- October 2020 (5)
- September 2020 (12)
- August 2020 (3)
- July 2020 (5)
- June 2020 (1)
- May 2020 (1)
- April 2020 (1)
- March 2020 (19)
- February 2020 (9)
- January 2020 (12)
- December 2019 (4)
- November 2019 (4)
- October 2019 (11)
- September 2019 (8)
- August 2019 (14)
- July 2019 (23)
- June 2019 (15)
- May 2019 (16)
- April 2019 (21)
- March 2019 (14)
- February 2019 (7)
- January 2019 (17)
- December 2018 (7)
- November 2018 (14)
- October 2018 (12)
- September 2018 (18)
- August 2018 (22)
- July 2018 (15)
- June 2018 (38)
- May 2018 (14)
- April 2018 (19)
- March 2018 (25)
- February 2018 (15)
- January 2018 (17)
- December 2017 (20)
- November 2017 (15)
- October 2017 (19)
- September 2017 (8)
- August 2017 (13)
- July 2017 (11)
- June 2017 (6)
- May 2017 (10)
- April 2017 (23)
- March 2017 (18)
- February 2017 (17)
- January 2017 (15)
- December 2016 (19)
- November 2016 (31)
- October 2016 (38)
- September 2016 (33)
- August 2016 (40)
- July 2016 (53)
- June 2016 (50)
- May 2016 (50)
- April 2016 (70)
- March 2016 (45)
- February 2016 (49)
- January 2016 (41)
- December 2015 (37)
- November 2015 (37)
- October 2015 (49)
- September 2015 (35)
- August 2015 (29)
- July 2015 (25)
- June 2015 (28)
- May 2015 (21)
- April 2015 (41)
- March 2015 (51)
- February 2015 (23)
- January 2015 (33)
- December 2014 (46)
- November 2014 (31)
- October 2014 (38)
- September 2014 (74)
- August 2014 (86)
- July 2014 (101)
- June 2014 (170)
- May 2014 (98)
- April 2014 (113)
- March 2014 (80)
- February 2014 (63)
- January 2014 (70)
- December 2013 (100)
- November 2013 (91)
- October 2013 (102)
- September 2013 (104)
- August 2013 (114)
- July 2013 (129)
- June 2013 (131)
- May 2013 (155)
- April 2013 (109)
- March 2013 (105)
- February 2013 (81)
Categories
- 0rphan drug status (211)
- 2020 APPROVALS (48)
- accelerated approval (1)
- Acute Hepatic Porphyria (1)
- Acute myeloid leukaemia (1)
- African medicine (6)
- AIDS (7)
- Alzheimer's (3)
- ANAESTHETIC (1)
- anaesthetics (4)
- analgesic (2)
- ANALYTICAL (1)
- ANDA (5)
- Anthony crasto (41)
- ANTI ACNE (2)
- ANTI DIABETES (1)
- ANTI FUNGAL (6)
- ANTI INFLAMATORY (2)
- anti tubeculosis (1)
- antibacterial (9)
- Antibiotics (5)
- ANTIBODIES (54)
- ANTICONVULSANT (1)
- Antiemetic (2)
- antiglaucoma (1)
- Antihypertensives (3)
- antiinfluenza (2)
- antimalarials (12)
- Antineoplastic (6)
- antiobesity (1)
- Antispasmodic (1)
- ANTITUSSIVE (1)
- Antiulcerative (1)
- Antivirals (5)
- APPROVALS 2021 (82)
- APPROVALS 2022 (44)
- APPROVALS 2023 (1)
- ARAB MEDICINE (5)
- Atopic dermatitis (1)
- Australia (1)
- AUSTRALIA 2021 (1)
- AWARD (12)
- AYURVEDA (78)
- Biosimilar drugs (39)
- BLA (4)
- BLOGS (28)
- Breakthrough Therapy Designation (67)
- canada (4)
- CANADA 2021 (1)
- cancer (160)
- cfda (6)
- CHINA 2011 (1)
- CHINA 2012 (1)
- CHINA 2018 (1)
- china 2019 (1)
- china pipeline (36)
- CHINESE HERBS (24)
- chronic kidney disease (1)
- CLINICAL TRIALS (10)
- COMPANIES (81)
- conference (5)
- Contrast agent (7)
- CORONAVIRUS (47)
- COVID-19 (45)
- CRL (1)
- CYSTIC FIBRIOSIS (2)
- Dengue (2)
- DIABETES (50)
- DNDi (1)
- Drug discovery (22)
- DRUG MARKETING (5)
- DRUG REVIEW (8)
- Duchenne muscular dystrophy (1)
- EMA (4)
- EU 2003 (1)
- EU 2005 (1)
- EU 2014 (5)
- EU 2015 (6)
- EU 2016 (4)
- EU 2017 (8)
- EU 2018 (5)
- EU 2020 (5)
- EU 2021 (11)
- EU 2022 (4)
- EU PIPELINE (61)
- EU SUBMISSION (32)
- EXTENDED USE (1)
- FAST TRACK FDA (74)
- FDA 15 (4)
- FDA 2010 (2)
- FDA 2011 (1)
- FDA 2012 (7)
- FDA 2013 (6)
- FDA 2014 (53)
- FDA 2015 (39)
- FDA 2016 (23)
- FDA 2017 (58)
- FDA 2018 (53)
- FDA 2019 (44)
- FDA 2020 (34)
- fda 2021 (45)
- FDA 2022 (24)
- FDA 2023 (1)
- Featured product (1)
- female sexual dysfunction (1)
- FIBROMYGALIA (1)
- flow synthesis (14)
- FORMULATION (14)
- GAIN (1)
- Gastric Proton Pump Inhibitor (1)
- Generating Antibiotic Incentives Now (1)
- GENERIC DRUG (106)
- GENERICS (22)
- glenmark (18)
- GLENMARK (16)
- GLIPTIN (1)
- GMP (10)
- gout (1)
- Greek medicine (3)
- hepatitis C viral infections (1)
- Herbals (8)
- HOMEOPATHY (3)
- HORMONE (1)
- Human medicines European Public Assessment Report EPAR (2)
- Hypertension (1)
- hypnotic (1)
- idiopathic pulmonary fibrosis (3)
- IMPLANTS (2)
- IND (1)
- IND 2017 (2)
- IND 2018 (3)
- IND 2021 (8)
- IND Filed (2)
- INDIA 2020 (5)
- INDIA 2022 (3)
- Insomnia (1)
- Investigational device exemption (IDE) approval (2)
- JAPAN 2009 (1)
- JAPAN 2013 (1)
- JAPAN 2014 (1)
- JAPAN 2015 (2)
- JAPAN 2016 (1)
- japan 2017 (6)
- JAPAN 2018 (10)
- japan 2019 (8)
- japan 2020 (10)
- JAPAN 2021 (11)
- JAPAN 2022 (14)
- Japan marketing (34)
- Japan pipeline (38)
- Korea (3)
- korea 2012 (2)
- korea 2016 (1)
- korea 2019 (1)
- Lactams (1)
- MAA (3)
- Macrolides (2)
- Malaria (17)
- MANUFACTURING (8)
- Market info (3)
- Marketing authorisation application EU (4)
- MEDICAL DEVICE (9)
- MIGRAINE (1)
- molybdenum cofactor deficiency (1)
- MONKEY POX (1)
- Monoclonal antibody (89)
- Nanotechnology (5)
- NCE (2)
- NDA (51)
- NDA JAPAN (3)
- neuropathic pain (1)
- Neutraceuticals (1)
- New Drug Application Resubmission FDA (5)
- NEW DRUGS (76)
- New drugs canada (5)
- New drugs china (6)
- New drugs EU (10)
- New drugs Japan (2)
- NEW USE DRUGS (1)
- Newzealand (2)
- NICE (2)
- non-Hodgkin's lymphoma (1)
- NUCLEOTIDES (1)
- obesity (3)
- OCCULAR (2)
- ocular hypertension (1)
- organic chemistry (12)
- osteoarthritis (2)
- PAIN (1)
- Parkinson's disease (1)
- PATENT (93)
- PATENTS (82)
- Peptide drugs (56)
- PFIZER (1)
- PHASE 1 (86)
- PHASE 3 (13)
- PHASE1 (142)
- Phase2 drugs (271)
- Phase3 drugs (301)
- plaque psoriasis (1)
- POLYMORPH (10)
- Preclinical china (14)
- Preclinical drugs (121)
- Premture ejaculation (3)
- prime designation (1)
- Priority review (88)
- PROCESS (39)
- Promising clips (9)
- Psoriasis (1)
- QbD (2)
- QIDP (23)
- radio labelled (3)
- RADIOACTIVE AGENT (3)
- RADIOLABELLED (8)
- Rare disease (3)
- RARE PEDIATRIC DISEASE REVIEW (1)
- Regenerative medicine (4)
- Regulatory (74)
- Resubmission FDA (2)
- REVIEW (10)
- rheumatoid arthritis (3)
- SCHLEROSING AGENT (2)
- Scottish Medicines Consortium (1)
- sex arousal (2)
- SFDA FAST TRACK (2)
- SINGAPORE (4)
- sNDA (12)
- sNDA JAPAN (2)
- Solid tumours (2)
- spectroscopy (16)
- SPOTLIGHT (53)
- Stem cells (3)
- SYNTHESIS (10)
- TIVE (1)
- TOXINS (1)
- Translational medicine (2)
- Transverse myletis (2)
- Tropical Disease Priority Review Voucher (1)
- UK (1)
- UNANI MEDICINE (2)
- Uncategorized (2,125)
- US HERBS (7)
- USFDA SUBMISSION (1)
- vaccine (26)
- veterinary (6)
- virus (1)
- VITAMINS (3)
- x ray contrast agent (3)
Recent Posts
- MAVORIXAFOR April 19, 2023
- SMARTCHEM FROM ROW2 TECHNOLOGIES March 9, 2023
- Amcenestrant (SAR 439859) January 26, 2023
- Myself Anthony Crasto up for grabs as Advisor API & INT, Chem. January 22, 2023
- ‘Top 10 Prominent & Great Personalities of the year 2022’ campaign by Fame Finders. ANTHONY CRASTO January 17, 2023
- SC-52458, FORASARTAN January 14, 2023
- Adagrasib January 4, 2023
- Nirsevimab December 27, 2022
- Olutasidenib December 20, 2022
- ABY 737 December 4, 2022
- Tolebrutinib, SAR 442168 November 26, 2022
- Mirvetuximab soravtansine-gynx November 16, 2022
- TEREVALEFIM November 2, 2022
- RELACORILANT October 31, 2022
- Tremelimumab October 27, 2022
ORGANIC SPECTROSCOPY

SUBSCRIBE

Enter your email address:
Delivered by FeedBurner
Subscribe to New Drug Approvals by EmailDR ANTHONY MELVIN CRASTO Ph.D
DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards
Personal Links
- my sites on the net
- DR ANTHONY MELVIN CRASTO
- GOOGLE GROUP ORGANIC PROCESS DEVELOPMENT
- mixxt
- epernicus
- scipeople
- jimdo
- yolasite
- my cv
- slidestaxx
- wordpress blog
- ABOUT ME
- BRANDSITE
- SKILLPAGES
- Academia.edu
- DIIGO
- WIX
- WIX BLOG
- ISSUU
- SCRIBD
- BIZ
- GOOGLE BLOG
- APNACIRCLE
- Eurekamoments in Organic Chemistry
- Organic Chemistry by Dr Anthony
- Green Chemistry International
- Technology Transfer
- Stereochemistry
- Spectroscopy
- Polymorphism
- Reactions in Org Chem
- DR ANTHONY MELVIN CRASTO Ph.D
- Pharmaceuticals
- Medicinal chemistry
- Organic chemistry literature
- Patent related site
- Green chemistry
- Reagents
- R & D
- Molecules
- Heterocyclic chem
- Sourcing
- NEW DRUG APPROVALS
- WORLD DRUG TRACKER
- Green Chemistry International
- drug regulatory affairs international
- ORGANIC SPECTROSCOPY INTERNATIONAL
- ORGANIC SYNTHESIS INTERNATIONAL
- ALL ABOUT DRUGS
- ORGANIC CHEMISTRY INTERNATIONAL
- GOOGLE PLUS
- Drug Scaleup and Manufacturing International
- MEDICINAL CHEMISTRY INTERNATIONAL
- DRUG SYNTHESIS INTERNATIONAL
- SLIDESHARE
- DRUGS WEB
- GOOGLE SCHOLAR
- MEDCHEM-amcrasto
- ONE ORGANIC CHEMISTONE DAY
- DRUG PATENTS INTERNATIONAL
- MEDCHEM ANTHONY CRASTO
- MEDCHEM anthony crasto
- Gravatar
- ZING ME VIETNAM
- RESEARCH GATE
- AWARDS
Verified Services
Pages
- About me
- All about drugs
- Bioavailability
- CLINICAL TRIALS
- Combinatorial Chemistry in Drug Design
- DISCLAIMER
- Drug Basics
- DRUG COMPANIES
- DRUG DESIGN
- DRUG DISCOVERY
- Drug Information
- DRUG NEWS
- DRUG PORTALS
- Drug resistance
- DRUG SITES
- DRUG SYNTHESIS
- DRUGS NDA
- DRUGS, FDA2012
- FDA -US
- GMP
- HEALTH CANADA
- HELP ME/ ACCOLADES
- HSA SINGAPORE
- INDA
- KOREA DRUG APPROVAL PROCESS
- MHLW JAPAN, 厚生労働省
- NMPA CHINA
- PATENT EXPIRY DATES 1/3
- PATENT EXPIRY DATES 2/3
- PATENT EXPIRY DATES 3/3
- Patent portals
- Polymorphism
- Regulations and Guidance
- Scientificupdate (UK) on a roll
- sFDA CHINA
- SOUTH AFRICA, MCC
- SPECIAL DRUGS
- Traditional Medicine
- WHAT IS A DRUG
- World drug tracker
Archives
- April 2023 (1)
- March 2023 (1)
- January 2023 (5)
- December 2022 (3)
- November 2022 (3)
- October 2022 (9)
- September 2022 (9)
- August 2022 (7)
- July 2022 (2)
- June 2022 (7)
- May 2022 (5)
- April 2022 (7)
- March 2022 (7)
- February 2022 (12)
- January 2022 (15)
- December 2021 (26)
- November 2021 (17)
- October 2021 (21)
- September 2021 (21)
- August 2021 (19)
- July 2021 (13)
- June 2021 (30)
- May 2021 (7)
- April 2021 (9)
- March 2021 (25)
- February 2021 (10)
- January 2021 (17)
- December 2020 (21)
- November 2020 (5)
- October 2020 (5)
- September 2020 (12)
- August 2020 (3)
- July 2020 (5)
- June 2020 (1)
- May 2020 (1)
- April 2020 (1)
- March 2020 (19)
- February 2020 (9)
- January 2020 (12)
- December 2019 (4)
- November 2019 (4)
- October 2019 (11)
- September 2019 (8)
- August 2019 (14)
- July 2019 (23)
- June 2019 (15)
- May 2019 (16)
- April 2019 (21)
- March 2019 (14)
- February 2019 (7)
- January 2019 (17)
- December 2018 (7)
- November 2018 (14)
- October 2018 (12)
- September 2018 (18)
- August 2018 (22)
- July 2018 (15)
- June 2018 (38)
- May 2018 (14)
- April 2018 (19)
- March 2018 (25)
- February 2018 (15)
- January 2018 (17)
- December 2017 (20)
- November 2017 (15)
- October 2017 (19)
- September 2017 (8)
- August 2017 (13)
- July 2017 (11)
- June 2017 (6)
- May 2017 (10)
- April 2017 (23)
- March 2017 (18)
- February 2017 (17)
- January 2017 (15)
- December 2016 (19)
- November 2016 (31)
- October 2016 (38)
- September 2016 (33)
- August 2016 (40)
- July 2016 (53)
- June 2016 (50)
- May 2016 (50)
- April 2016 (70)
- March 2016 (45)
- February 2016 (49)
- January 2016 (41)
- December 2015 (37)
- November 2015 (37)
- October 2015 (49)
- September 2015 (35)
- August 2015 (29)
- July 2015 (25)
- June 2015 (28)
- May 2015 (21)
- April 2015 (41)
- March 2015 (51)
- February 2015 (23)
- January 2015 (33)
- December 2014 (46)
- November 2014 (31)
- October 2014 (38)
- September 2014 (74)
- August 2014 (86)
- July 2014 (101)
- June 2014 (170)
- May 2014 (98)
- April 2014 (113)
- March 2014 (80)
- February 2014 (63)
- January 2014 (70)
- December 2013 (100)
- November 2013 (91)
- October 2013 (102)
- September 2013 (104)
- August 2013 (114)
- July 2013 (129)
- June 2013 (131)
- May 2013 (155)
- April 2013 (109)
- March 2013 (105)
- February 2013 (81)
Categories
- 0rphan drug status (211)
- 2020 APPROVALS (48)
- accelerated approval (1)
- Acute Hepatic Porphyria (1)
- Acute myeloid leukaemia (1)
- African medicine (6)
- AIDS (7)
- Alzheimer's (3)
- ANAESTHETIC (1)
- anaesthetics (4)
- analgesic (2)
- ANALYTICAL (1)
- ANDA (5)
- Anthony crasto (41)
- ANTI ACNE (2)
- ANTI DIABETES (1)
- ANTI FUNGAL (6)
- ANTI INFLAMATORY (2)
- anti tubeculosis (1)
- antibacterial (9)
- Antibiotics (5)
- ANTIBODIES (54)
- ANTICONVULSANT (1)
- Antiemetic (2)
- antiglaucoma (1)
- Antihypertensives (3)
- antiinfluenza (2)
- antimalarials (12)
- Antineoplastic (6)
- antiobesity (1)
- Antispasmodic (1)
- ANTITUSSIVE (1)
- Antiulcerative (1)
- Antivirals (5)
- APPROVALS 2021 (82)
- APPROVALS 2022 (44)
- APPROVALS 2023 (1)
- ARAB MEDICINE (5)
- Atopic dermatitis (1)
- Australia (1)
- AUSTRALIA 2021 (1)
- AWARD (12)
- AYURVEDA (78)
- Biosimilar drugs (39)
- BLA (4)
- BLOGS (28)
- Breakthrough Therapy Designation (67)
- canada (4)
- CANADA 2021 (1)
- cancer (160)
- cfda (6)
- CHINA 2011 (1)
- CHINA 2012 (1)
- CHINA 2018 (1)
- china 2019 (1)
- china pipeline (36)
- CHINESE HERBS (24)
- chronic kidney disease (1)
- CLINICAL TRIALS (10)
- COMPANIES (81)
- conference (5)
- Contrast agent (7)
- CORONAVIRUS (47)
- COVID-19 (45)
- CRL (1)
- CYSTIC FIBRIOSIS (2)
- Dengue (2)
- DIABETES (50)
- DNDi (1)
- Drug discovery (22)
- DRUG MARKETING (5)
- DRUG REVIEW (8)
- Duchenne muscular dystrophy (1)
- EMA (4)
- EU 2003 (1)
- EU 2005 (1)
- EU 2014 (5)
- EU 2015 (6)
- EU 2016 (4)
- EU 2017 (8)
- EU 2018 (5)
- EU 2020 (5)
- EU 2021 (11)
- EU 2022 (4)
- EU PIPELINE (61)
- EU SUBMISSION (32)
- EXTENDED USE (1)
- FAST TRACK FDA (74)
- FDA 15 (4)
- FDA 2010 (2)
- FDA 2011 (1)
- FDA 2012 (7)
- FDA 2013 (6)
- FDA 2014 (53)
- FDA 2015 (39)
- FDA 2016 (23)
- FDA 2017 (58)
- FDA 2018 (53)
- FDA 2019 (44)
- FDA 2020 (34)
- fda 2021 (45)
- FDA 2022 (24)
- FDA 2023 (1)
- Featured product (1)
- female sexual dysfunction (1)
- FIBROMYGALIA (1)
- flow synthesis (14)
- FORMULATION (14)
- GAIN (1)
- Gastric Proton Pump Inhibitor (1)
- Generating Antibiotic Incentives Now (1)
- GENERIC DRUG (106)
- GENERICS (22)
- glenmark (18)
- GLENMARK (16)
- GLIPTIN (1)
- GMP (10)
- gout (1)
- Greek medicine (3)
- hepatitis C viral infections (1)
- Herbals (8)
- HOMEOPATHY (3)
- HORMONE (1)
- Human medicines European Public Assessment Report EPAR (2)
- Hypertension (1)
- hypnotic (1)
- idiopathic pulmonary fibrosis (3)
- IMPLANTS (2)
- IND (1)
- IND 2017 (2)
- IND 2018 (3)
- IND 2021 (8)
- IND Filed (2)
- INDIA 2020 (5)
- INDIA 2022 (3)
- Insomnia (1)
- Investigational device exemption (IDE) approval (2)
- JAPAN 2009 (1)
- JAPAN 2013 (1)
- JAPAN 2014 (1)
- JAPAN 2015 (2)
- JAPAN 2016 (1)
- japan 2017 (6)
- JAPAN 2018 (10)
- japan 2019 (8)
- japan 2020 (10)
- JAPAN 2021 (11)
- JAPAN 2022 (14)
- Japan marketing (34)
- Japan pipeline (38)
- Korea (3)
- korea 2012 (2)
- korea 2016 (1)
- korea 2019 (1)
- Lactams (1)
- MAA (3)
- Macrolides (2)
- Malaria (17)
- MANUFACTURING (8)
- Market info (3)
- Marketing authorisation application EU (4)
- MEDICAL DEVICE (9)
- MIGRAINE (1)
- molybdenum cofactor deficiency (1)
- MONKEY POX (1)
- Monoclonal antibody (89)
- Nanotechnology (5)
- NCE (2)
- NDA (51)
- NDA JAPAN (3)
- neuropathic pain (1)
- Neutraceuticals (1)
- New Drug Application Resubmission FDA (5)
- NEW DRUGS (76)
- New drugs canada (5)
- New drugs china (6)
- New drugs EU (10)
- New drugs Japan (2)
- NEW USE DRUGS (1)
- Newzealand (2)
- NICE (2)
- non-Hodgkin's lymphoma (1)
- NUCLEOTIDES (1)
- obesity (3)
- OCCULAR (2)
- ocular hypertension (1)
- organic chemistry (12)
- osteoarthritis (2)
- PAIN (1)
- Parkinson's disease (1)
- PATENT (93)
- PATENTS (82)
- Peptide drugs (56)
- PFIZER (1)
- PHASE 1 (86)
- PHASE 3 (13)
- PHASE1 (142)
- Phase2 drugs (271)
- Phase3 drugs (301)
- plaque psoriasis (1)
- POLYMORPH (10)
- Preclinical china (14)
- Preclinical drugs (121)
- Premture ejaculation (3)
- prime designation (1)
- Priority review (88)
- PROCESS (39)
- Promising clips (9)
- Psoriasis (1)
- QbD (2)
- QIDP (23)
- radio labelled (3)
- RADIOACTIVE AGENT (3)
- RADIOLABELLED (8)
- Rare disease (3)
- RARE PEDIATRIC DISEASE REVIEW (1)
- Regenerative medicine (4)
- Regulatory (74)
- Resubmission FDA (2)
- REVIEW (10)
- rheumatoid arthritis (3)
- SCHLEROSING AGENT (2)
- Scottish Medicines Consortium (1)
- sex arousal (2)
- SFDA FAST TRACK (2)
- SINGAPORE (4)
- sNDA (12)
- sNDA JAPAN (2)
- Solid tumours (2)
- spectroscopy (16)
- SPOTLIGHT (53)
- Stem cells (3)
- SYNTHESIS (10)
- TIVE (1)
- TOXINS (1)
- Translational medicine (2)
- Transverse myletis (2)
- Tropical Disease Priority Review Voucher (1)
- UK (1)
- UNANI MEDICINE (2)
- Uncategorized (2,125)
- US HERBS (7)
- USFDA SUBMISSION (1)
- vaccine (26)
- veterinary (6)
- virus (1)
- VITAMINS (3)
- x ray contrast agent (3)
Recent Comments
SEARCH THIS BLOG
(±)-Integrifolin, Compound from plants keeps human cancer cells from multipying
June 20, 2016 2:40 pm / Leave a comment
CAS 89647-87-0
-
- Azuleno[4,5-b]furan-2(3H)-one, decahydro-4,8-dihydroxy-3,6,9-tris(methylene)-, [3aR-(3aα,4β,6aα,8β,9aα,9bβ)]-
- (3aR,4R,6aR,8S,9aR,9bR)-Decahydro-4,8-dihydroxy-3,6,9-tris(methylene)azuleno[4,5-b]furan-2(3H)-one
- 8-epi-Deacylcynaropicrin
- 8β-Hydroxyzaluzanin C
- Integrifolin (guaianolide)
PATENT
Paper
Journal title : Bulletin of the Korean Chemical Society
Volume 33, Issue 1, 2012, pp.337-340
Publisher : Korean Chemical Society
DOI : 10.5012/bkcs.2012.33.1.337
BLOG POST FROM CHEMISTRY VIEWS, WILEY
(±)-Integrifolin
Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Total Synthesis of (±)-Integrifolin
Compound from plants keeps human cancer cells from multipying
Read more at Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Weight control is an important concern of human beings, both for medical (pharmaceutical and/or nutraceutical) as well as non-therapeutic, e.g. cosmetic, reasons. More importantly, excessive accumulation of body fat (i.e. obesity (= adiposity), especially with excessive fat in the ventral region and surrounding the viscera) can be dangerous and has been linked to health problems such as type II diabetes, hypertension, heart disease, atherosclerosis (where more than two of the preceding disorders are present, the condition is often called “Metabolic Syndrome” or “syndrome X”), hyperlipidemia, coronary heart disease, stroke, breast and colon cancer, sleep apnoea, gallbladder disease, reproductive disorders such as polycystic ovarian syndrome, gastroesophageal reflux disease, increased incidence of complications of general anesthesia, fatty liver, gout or thromboembolism (see, e.g., Kopelman, Nature 404: 635-43 (2000)). Obesity reduces life-span and carries a serious risk of the co-morbidities listed above, as well disorders such as infections, varicose veins,
acanthosis nigricans, eczema, exercise intolerance, insulin resistance, hypertension hypercholesterolemia, cholelithiasis, orthopedic injury, and thromboembolic disease (Rissanen et al, Br. Med. J. 301 : 835-7 (1990)). Obesity is one of the main factors in the development of cardiovascular diseases. As a side effect the levels of cholesterol, blood pressure, blood sugar and uric acid in obese people are usually higher than those of persons of normal weight. The morbidity from coronary heart disease among the overweight people is increased as well. Among the people aged 40-50, mortality will rise about 1% when body weight increases by 0.5 kg and the death rate will increase 74% when body weight exceeds 25% of the standard. The prevalence of obesity in the United States has more than doubled since the turn of the last century (whole population) and more than tripled within the last 30 years among children aged from 6 to 11. This problem more and more becomes a disease risk also in Europe. In Germany, particularly many people have been found to suffer from overweight recently, already 25% of the young people, children and adolescents there are affected by obesity and related disorders. Furthermore, being overweight is considered by the majority of the Western population as unattractive.
Overweight and obesity result from an imbalance between the calories consumed and the calories used by the body. When the calories consumed exceed the calories burned, the body is in positive energy balance and over time weight gain will occur. The excess calories are stored in the fat cells. When the calories burned exceed the calories consumed, the body is in negative energy balance and over time weight loss will occur.
Determinants of obesity include social factors, psychological factors, genetic factors, developmental factors and decreased physical activity. Some components of a comprehensive weight loss programs include medical assessment, behavioural and dietary modification, nutrition education, mental and cognitive restructuring, increased physical activity, and long term follow-up.
An increasing interest by consumers in the maintenance or reduction of their body weight can be found. This leads to a demand for products useful for these purposes. Preferred are such food products which can conveniently be consumed as part of the daily diet, for example meal replacer products, such as meal replacer bars and beverages. These are usually designed for use as a single-serving food product to replace one or two meals a day.
An issue is that often a saturating effect is missed when such products are consumed, resulting in hunger feelings only a relatively short time after consummation or even in the lack of a saturation feeling already directly after consummation.
Summing up, there remains a need for new safe and effective compositions for promoting weight loss and/or loss of body fat in subjects such as humans. The problem to be solved by the present invention is therefore to find compositions or compounds useful in the treatment of obesity; and/or for improving the total cholesterol HDIJLDL ratio.
Phytochemistry provides a large pool of compounds and compositions to be looked at whether they are able to solve this problem.
The present invention provides methods and compositions useful in the control, treatment and prevention of obesity and obesity-related conditions, disorders, and diseases; and/or and/or for improving the total cholesterol HDL/LDL ratio.
Rosinski, G., et al., Endocrinological Frontiers in Phyiological Insect Ecology, Wroclow Technical University Press, Wroclow 1989, describe that certain tricyclic sequiterpene lactones, such as grossheimin and repin, showed inhibition of larval growth and antifeeding activity in Mealworm (Tenebrio σιοΐϊίοή. Grossheimin shows no anti-feeding but little decrease of absorption of digested food constituents and a little decrease in efficiency in digesting. Repin exhibit low effects at all. Both compounds show no effect on lipid levels in blood.
Shimoda, H., et al, Bioinorganic & Medicinal Chemistry Letters 13 (2003), 223-228, describe that methanolic extracts from Artichoke (Cynara sclolymus L.) with cynaropicrin, aguerin B and grossheimin as components and certain sesquiterpene glycosides suppress serum triglyceride elevation in olive oil-loaded mice. Some of these compounds exhibit a moderate short term (2 hours after olive oil administration) anti-hyperlipidemic activity presented as a lowering of the serum triglyceride (serum TG) concentrations, the long term (6 hours) show in the case of cynaropicrin and aguerine B an increase of the serum TG. Furthermore the authors present data of the gastric emptying (GE) of a methanolic ectract of artichoke. They determine a significantly inhibited GE. However, as shown below, this mechanism is not an explanation for the anti obesity effect shown in the present invention (see Example 1 ).
Fritzsche, J., et al., Eur. Food Res. Technol. 215, 149-157 (2002) describe the effect of certain isolated artichoke leaflet extract components with cholesterol lowering potential. Ahn, E.M-., et al, Arch Pharm. res. 29(1 1 ), 937-941 , 2006, shows ACAT inhibitory activity for two sesquiterpene lactones. KR 20040070985 also shows an effect of certain sesquiterpene lactone derivatives on cholesterol biosynthesis involved enzymes. Gebhard, R., Phytother. Res. 16, 368-372 (2002) and J. Pharmacol. Exp. Ther. 286(3), 1 122-1 128 (1998), shows
enforcement of cholesterol biosynthesis inhibition in HepG2 cells by artichoke extracts. WO 2007/006391 also claims reduction in cholesterol by certain Cynara scolymus variety extracts.
Other reported activities of tricyclic sesquiterpene lactones are antioxidant activity (European Food Research & Technology (2002), 215(2): 149-157), inhibitors of NF kb (Food Style 21 (2007), 1 1 (6): 54-56; JP 2006-206532), serum triglyceride increase-inhibitory effect (Kagaku Kogyo (2006), 57(10): 740-745), hypoglycaemic effect (J. Trad. Med. (2003), 20(2): 57-61), bitter taste (DE 2654184). Any beneficial effects are included in this invention by reference.
None of the documents suggest that a control and treatment of obesity and body fat in warmblooded animals might be possible.
Cynaropicrin, a tricyclic sesquiterpene lactone causes in vivo a strong weight loss. More surprisingly it was found that this effect is not correlated to a decrease in food intake. The weight balance is not affected by reduction of assimilation efficiency; the decrease of body fat and body weight is presumably caused by effects on energy metabolism. Surprisingly, it was found in addition that cynaropicrin also allows for improving the total cholesterol HDL7LDL ratio
Tricyclic sequiterpene lactones or known ingredients of plants of the subclass Asterides, especially from the family of Asteraceae, more specifically from species of the genera of the list consisting of Achilea, Acroptilon, Agranthus, Ainsliaea, Ajania, Amberboa, Andryala, Artemisia, Aster, Bisphopanthus, Brachylaena, Calea, Calycocorsus, Cartolepsis, Centaurea, Cheirolophus, Chrysanthemum, Cousinia, Crepis, Cynara, Eupatorium, Greenmaniella, Grossheimia, Hemistaptia, Ixeris, Jurinea, Lapsana, Lasiolaena, Liatris, Lychnophora, Macroclinidium, Mikania, Otanthus, Pleiotaxis, Prenanthes, Pseudostifftia, Ptilostemon,
Rhaponticum, Santolina, Saussurea, Serratula, Sonchus, Stevia, Taeckholmia, Tanacetum, Tricholepis, Vernonia, Volutarella, Zaluzania; even more specifically from species of the list consisting of Achillea clypeolata, Achillea collina, Acroptilon repens, Agrianthus pungens, Ainsliaea fragrans, Ajania fastigiata, Ajania fruticulosa, Amberboa lippi, Amberboa muricata, Amberboa ramose**, Amberboa tubuliflora and other Amberboa spp.*, Andryala integrifolia, Andryala pinnatifida, Artemisia absinthium, Artemisia cana, Artemisia douglasiana, Artemisia fastigiata, Artemisia franserioides, Artemisia montana, Artemisia sylvatica, Artemisia
tripartita, Aster auriculatus, Bishopanthus soliceps, Brachylaena nereifolia, Brachylaena perrieri, Calea jamaicensis, Calea solidaginea, Calycocorsus stipitatus, Cartolepsis intermedia, Centaurea babylonica, Centaurea bella, Centaurea canariensis*, Centaurea clementei, Centaurea conicum, Centaurea dealbata, Centaurea declinata, Centaurea glastifolia, Centaurea hermanii, Centaurea hyrcanica, Centaurea intermedia, Centaurea janeri, Centaurea kalscyi, Centaurea kandavanensis, Centaurea kotschyi, Centaurea linifolia, Centaurea macrocephala, Centaurea musimomum, Centaurea nicolai, Centaurea pabotii, Centaurea pseudosinaica, Centaurea repens, Centaurea salonitana, Centaurea scoparia, Centaurea sinaica, Centaurea solstitialis, Centaurea tweediei and other Centaurea spp. *, Cheirolophus uliginosus, Chrysanthemum boreale, Cousin ia canescens, Cousinia conifera, Cousinia picheriana, Cousinia piptocephala, Crepis capillaris, Crepis conyzifolia, Crepis crocea, Crepis japonica, Crepis pyrenaica, Crepis tectorum, Crepis virens, Crepis zacintha, Cynara alba, Cynara algarbiensis, Cynara auranitica, Cynara baetica, Cynara cardunculus, Cynara cornigera, Cynara cyrenaica, Cynara humilis, Cynara hystrix, Cynara syriaca, Cynara scolymus**, Cynara sibthorpiana and other Cynara spp.*, Eupatorium anomalum,
Eupatorium chinense, Eupatorium lindleyanum, Eupatorium mohrii, Eupatorium
rotundifolium, Eupatorium semialatum, Greenmaniella resinosa, Grossheimia
macrocephala** and other Grossheimia spp. *, Hemisteptia lyrata, Ixeris chinensis, Ixeris debilis, Ixeris dentata, Ixeris repens, Ixeris stolonifera, Jurinea carduiformis, Jurinea derderioides, Jurinea maxima, Lapsana capillaris, Lapsana communis, Lasiolaena morii, Lasiolaena santosii, Liatris chapmanii, Liatris gracilis, Liatris pycnostachya, Lychnophora blanchetii, Macroclinidium trilobum, Mikania hoehnei, Otanthus maritimus, Pleiotaxis rugosa, Prenanthes acerifolia, Pseudostifftia kingii, Ptilostemon diacanthus, Ptilostemon
gnaphaloides, Rhaponticum serratuloides, Santolina jamaicensis, Saussurea affinis,
Saussurea elegans, Saussurea involucrata, Saussurea laniceps, Saussurea neopulchella** and other Sauusurea spp. *, Serratula strangulata, Sonchus arborea, Stevia sanguinea, Taeckholmia arborea, Taeckholmia pinnata, Tanacetum fruticulosum, Tanacetum
parthenium, Tricholepis glaberrima** and other Tricholepsis spp. *, Vernonia arkansana, Vernonia nitidula, Vernonia noveboracensis, Vernonia profuga, Vernonia sublutea,
Volutarella divaricata, Zaiuzania resinosa; and can potentially be isolated from any part of the plants. Those genera and/or species marked with an asterisk (*) and especially those species marked with two asterisks (**) are especially preferred.
Appropriate plant material can be obtained from various sources, e.g. from:
Alfred Galke GmbH, Gittelde/Harz, Germany; Miiggenburg Pflanzliche Rohstoffe, Bad Bramstedt, Germany; Friedrich Nature Discovery, Euskirchen, Germany; VitaPlant AG, Uttwil, Switzerland; Amoros Nature SL, Hostalric, Spain.
(±)-Integrifolin
Banksia integrifolia
Coast Banksia
Family: Proteaceae
Banksia integrifolia is a tall shrub or small tree 6 – 16m tall. It is common in sandy coastal areas, but also grows in the forests of tablelands. The light grey bark is hard and rough.
Mature leaves 5 -10 cm long, are stiff, entire (untoothed), dull dark green above and hairy-white underneath. They are generally lanceolate. Younger leaves are irregularly toothed and shorter than the mature leaves. The species name ‘integrifolia’ means whole-leaved.
The pale yellow flower spikes of Banksia integrifolia range from 7-14cm long and 7cm wide. The bent styles emerge from individual flowers on the spike, straightening and spreading.
A short time after flowering, the seed pods protrude cleanly from the woody cone and open to shed black, papery, winged seeds.
Banksia integrifolia flowers from January to June.
https://www.jstage.jst.go.jp/article/cpb1958/33/8/33_8_3361/_pdf
PAPER
http://onlinelibrary.wiley.com/doi/10.1002/chem.201601275/abstract
Total Synthesis of (±)-Integrifolin
- DOI: 10.1002/chem.201601275
///////(±)-Integrifolin, human cancer cells, multipying
C=C1C(=O)O[C@@H]2[C@H]3C(=C)[C@@H](O)C[C@H]3C(=C)C[C@@H](O)[C@@H]12
European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014
July 14, 2014 7:57 am / 1 Comment on European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014
10/07/2014
European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014
Thirty-nine medicines for human use were recommended for marketing authorisationby the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in the first half of 2014, compared with 44 in first half of 2013 and 33 in first half of 2012.
This figure includes a number of new innovative medicines with the potential to meet unmet medical needs, treat diseases for which no treatments were previously available or bring significant added benefit to patients over existing therapies. Among these medicines are the anticancer medicines Mekinist (trametinib) and Gazyvaro (obinutuzumab), the anti-inflammatory* Entyvio (vedolizumab), the anti-infective Daklinza (daclatasvir), as well as Translarna (ataluren) and Sylvant (siltuximab), which are both intended for the treatment of rare conditions.
In parallel, the number of medicines recommended for approval via the European Union centralised procedure based on generic or informed consent applications has decreased compared with the first half of 2013 (6 versus 13).
More than two in three applicants received scientific advice from the CHMP during the development phase of their medicine, and for innovative medicines four in five applicants received such advice. This is a significant increase compared with the first half of 2013 (when one in two applicants received scientific advice), and mirrors the growing number of requests for scientific advice received by the Agency.
Confirming the trend observed in the past few years, the number of new medicines intended for the treatment of rare diseases is steadily increasing, providing treatments for patients who often have only few or no options. In the first half of 2014, eight medicines were recommended for the treatment of rare diseases. This number includes three medicines for which the CHMP recommended conditional approval but whose applications were withdrawn by the sponsor prior to a final decision by the European Commission **.
Conditional approval is one of the Agency’s mechanisms to provide early patient access to medicines that fulfill unmet medical needs or address life-threatening diseases. The CHMP also used this mechanism for the recommendation of the first treatment for Duchenne muscular dystrophy (Translarna), a life-threatening condition.
The CHMP granted two positive opinions after an accelerated assessment for the medicines Sylvant and Daklinza; this mechanism aims to speed up the assessment of medicines that are expected to be of major public health interest particularly from the point of view of therapeutic innovation.
The CHMP also gave an opinion on the use of a new combination product in the treatment of hepatitis C virus (HCV) infection in a compassionate use programme (ledipasvir and sofosbuvir). These programmes are intended to give patients with a life-threatening, long-lasting or seriously disabling disease access to treatments that are still under development. The treatment paradigm of hepatitis C is currently shifting rapidly, with the development of several new classes of direct-acting antivirals. By recommending the conduct of three compassionate use programmes and the marketing authorisation of three new medicines for HCV infection over the past eight months, the Agency is actively supporting this shift which is expected to bring significant added benefit to patients.
Notes
* On Friday 11 July 2014 at 11:00 the statement, ‘the anti-infectives Entyvio (vedolizumab) and Daklinza (daclatasvir)’ was corrected to ‘the anti-inflammatory Entyvio (vedolizumab), the anti-infective Daklinza (daclatasvir)’.
** The CHMP had recommended a conditional approval for Vynfinit (vintafolide) and its companion diagnostics Folcepri (etarfolatide) and Neocepri (folic acid). After authorisation, the company was to provide confirmatory data from an ongoing study with Vynfinit. However, before the authorisation process could be completed by the European Commission, preliminary data from this study became available which showed that the study could not confirm the benefit of Vynfinit in ovarian cancer patients. Therefore, the company terminated the study and decided to withdraw the applications.
Stem Cells from Muscle Can Repair Nerve Damage After Injury, Pitt Researchers Show
April 7, 2014 12:15 pm / 1 Comment on Stem Cells from Muscle Can Repair Nerve Damage After Injury, Pitt Researchers Show

In some ground-breaking research, scientists have been able to use stem cells derived from human muscle tissue to repair nerve damage and restore function after injury to sciatic nerves.
And, even after 12 weeks, the regenerated nerve looked and functioned as a normal nerve.
Link to Story:
http://www.upmc.com/media/NewsReleases/2014/Pages/pitt-study-stem-cells-repair-nerve-damage.aspx
Regenerative Medicine: Polymer coating could help stem cells target inflamed blood vessels to regrow healthy tissue
April 30, 2013 3:33 am / 6 Comments on Regenerative Medicine: Polymer coating could help stem cells target inflamed blood vessels to regrow healthy tissue
People with chronic diseases like diabetes and multiple sclerosis have inflamed, leaky blood vessels, heightening their risk of heart attack and stroke. Some scientists envision using a patient’s own stem cells to regrow healthy tissue to plug the leaks and calm inflammation. A new polymer coating could help these stem cells find and adhere to inflamed endothelial tissue (J. Am. Chem. Soc., DOI: 10.1021/ja400636d).
read all at
http://cen.acs.org/articles/91/web/2013/04/Putting-Stem-Cells-Place.html
Serving The Chemical, Life Sciences & Laboratory Worlds